Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24925263 | 0.84 | CYP1A2 (0.43) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL25594845 | 0.83 | CYP1A2 (0.44) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL1008113 | 0.81 | CYP1A2 (0.48) | CYP1A2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6381453 | 0.81 | ALDH1A1 (0.42) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL15273696 | 0.80 | ALDH1A1 (0.41) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL3127245 | 0.79 | ALDH1A1 (0.46) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL6381168 | 0.77 | CYP1A2 (0.44) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2POLB | |
| SCHEMBL3129684 | 0.76 | ALDH1A1 (0.46) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL22275219 | 0.76 | ALDH1A1 (0.43) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL22716058 | 0.75 | CDC7 (0.49) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023086319-A1 | 6-HE TERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022129913-A1 | ALKYNE DERIVATIVES AS INHIBITORS OF C-ABL | BENEVOLENTAI BIO LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| EP-3986559-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2020260871-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | CYP1A2 60/4885ALDH1A1 1758/4885CYP2C19 160/4885 |
| US-20190016726-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | CYP1A2 154/4885ALDH1A1 2096/4885CYP2C19 435/4885 |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | CYP1A2 957/4885ALDH1A1 651/4885CYP2C19 620/4885 |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CYP1A2 3220/4885ALDH1A1 3735/4885CYP2C19 2386/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | CYP1A2 79/4885ALDH1A1 1849/4885CYP2C19 439/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | CYP1A2 154/4885ALDH1A1 2096/4885CYP2C19 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.